About immuron - IMRN
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.
IMRN At a Glance
Immuron Ltd.
25-37 Chapman Street
Blackburn, Victoria (VIC) 3131
| Phone | 61-3-8892-4802 | Revenue | 5.23M | |
| Industry | Pharmaceuticals: Major | Net Income | -2,601,190.50 | |
| Sector | Health Technology | 2026 Sales Growth | 10.756% | |
| Fiscal Year-end | 06 / 2027 | Employees | N/A | |
| View SEC Filings |
IMRN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.637 |
| Price to Book Ratio | 1.122 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
IMRN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 6.034 |
| Total Asset Turnover | 0.668 |
IMRN Liquidity
| Current Ratio | 7.169 |
| Quick Ratio | 5.895 |
| Cash Ratio | 5.051 |
IMRN Profitability
| Gross Margin | 64.497 |
| Operating Margin | -61.391 |
| Pretax Margin | -57.85 |
| Net Margin | -49.765 |
| Return on Assets | -33.263 |
| Return on Equity | -40.287 |
| Return on Total Capital | N/A |
| Return on Invested Capital | N/A |
IMRN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |